Clinical trials: Ocular Melanoma
Choroidal Melanoma, Indeterminate Lesions
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- NCT07421739
- Testing
- Non-interventional, digital, patient-reported, study
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Aura Biosciences
Choroidal Melanoma, Indeterminate Lesions
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- CoMpass (NCT06007690)
- Testing
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Aura Biosciences
Uveal Melanoma, Ocular Melanoma
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
- Trial name
- NCT05524935
- Testing
- Pembrolizumab, Olaparib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension
- Trial name
- NCT01989572
- Testing
- Laboratory Biomarker Analysis, Sargramostim, Tyrosinase Peptide
- Where
- 148 sites in United States
- Volunteers
- 815 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Melanoma, Metastatic Melanoma
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
- Trial name
- NCT06940739
- Testing
- IOV-3001
- Where
- 5 sites in United States, Australia
- Volunteers
- 42 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Ocular Melanoma
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients.
- Trial name
- NADOM (NCT05187884)
- Testing
- Darovasertib
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- St Vincent's Hospital, Sydney
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
This phase I trial finds out the side effects and possible benefits of stereotactic radiosurgery and immune checkpoint inhibitors with NovoTTF-100M for the treating of melanoma that has spread to the brain (brain metastases).
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
- Trial name
- NCT05341349
- Testing
- Ipilimumab, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Metastatic Melanoma, Unresectable Melanoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a lymphodepleting chemotherapy regimen and before…
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma
- Trial name
- NCT05628883
- Testing
- TBio-4101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Somatic Mutation, Ocular Melanoma
iSITE: Investigation of Somatic Alterations in Tumours of the Eye
Modern DNA sequencing technologies enable researchers to identify mutations that have been acquired during the lifetime of patients (somatic mutations).
- Trial name
- iSITE (NCT06861647)
- Testing
- sample collection, Discussing study/seeking consent, Completion of Study Questionnaire
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- The Wellcome Sanger Institute
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Ocular Melanoma
Eye Plaque Brachytherapy for Ocular Melanoma
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes.
- Trial name
- PROMPT (NCT06432660)
- Testing
- Data collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Ocular Melanoma
Resistance Exercise in Patients With Ocular Melanoma
Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation.
- Trial name
- IHOPE (NCT06970236)
- Testing
- Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Valencia
Ocular Melanoma
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
This is an open-label, multi-center, single-arm clinical phase II study to further characterize the efficacy and safety of ipilimumab in patients with or without systemic pretreatment metastatic ocular melanoma.
- Trial name
- DeCOG (NCT01355120)
- Testing
- Ipilimumab
- Where
- 25 sites in Germany
- Volunteers
- 171 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Ocular Melanoma
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity.
- Trial name
- PROTECT (NCT03172299)
- Testing
- Aflibercept Injection, False injection
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Uveal Melanoma, Ocular Melanoma
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT04417530
- Testing
- AU-011, Suprachoroidal Microinjector, PDT Laser
- Where
- 22 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aura Biosciences
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ocular Sebaceous Carcinoma, Ocular Basal Cell Carcinoma
Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
The study involves enrollment of patients with sebaceous carcinoma, Merkel's carcinoma, Porocarcinoma, Melanoma, and squamous cell Ca of the ocular surface and adnexa both primary and relapsed after surgical and/or…
- Conditions
- Ocular Sebaceous Carcinoma, Ocular Basal Cell Carcinoma, Ocular Surface Squamous Neoplasia, Merkel Cell Carcinoma, Unspecified
- Trial name
- BLS (NCT05797415)
- Testing
- Sentinel Lymph Node Biopsy
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Melanoma, Ocular Melanoma
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants.
- Conditions
- Melanoma, Ocular Melanoma, Uveal Melanoma
- Trial name
- Mel66 (NCT04364230)
- Testing
- 6MHP, NeoAg-mBRAF, PolyICLC
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Craig L Slingluff, Jr